Meet Ajit Bisen, M.D.
Ajit K. Bisen, M.D., MBA
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Affiliate Faculty, Clinical Cancer Genetics Program, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Affiliate Faculty, Clinical Cancer Genetics Program, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
2018 | UT Dallas Jindal School of Management, Dallas, Texas, US, MBA in Healthcare Leadership and Management |
2009 | St. George’s University School of Medicine, St. George, GD, MD |
2004 | University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US, BS in Computer Science |
Postgraduate Training
2017-2020 | Clinical Fellowship, Hematology and Oncology, UT Southwestern Medical Center, Dallas, Texas |
2013-2014 | Clinical Fellowship, Hematology and Oncology, The Ohio State University, Columbus, Ohio |
2009-2012 | Clinical Residency, Internal Medicine, Penn State University Hershey Medical Center, Hershey, Pennsylvania |
Board Certifications
2020 | American Board of Medical Oncology |
2020 | American Board of Hematology |
2012 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Assistant Professor, The University of Texas Southwestern Medical Center, Dallas, Texas, 2014 - 2017
Assistant Professor, Parkland Hospital, Dallas, Texas, 2014 - 2015
Clinical Assistant Professor of Medicine, Penn State College of Medicine, Hershey, Pennsylvania, 2013 - 2013
Assistant Professor, Lebanon VA Medical Center, Lebanon, Pennsylvania, 2012 - 2013
Administrative Appointments/Responsibilities
General Oncology Faculty Lead at West Houston, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - Present
Other Appointments/Responsibilities
Annual Breast Health Awareness Program Expert Speaker, Indian American Cancer Network (iacannetwork.org), 2024 - Present
Faculty Collaborator for Pre-Health Honors Research Course, Office of Pre-Health Studies, Science & Health Living and Learning Center, Baylor University, Waco, Texas, 2024 - Present
Career Day Speaker, Obra D Tompkins High School, Katy, Texas, 2024 - Present
MD Anderson Cancer Center Community Relations Ambassador, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Medical Advisory Board Member, Indian American Cancer Network (iacannetwork.org), 2023 - Present
Assistant Professor, Oncology Hospitalist, UT Southwestern Medical Center, Dallas, Texas, 2015 - 2017
Institutional Committee Activities
Secondary Tumor Board Moderator, Department of Breast Medical Oncology Weekly Case Conference, 2024 - Present
Department Wellness Officer, Department of General Oncology, 2024 - Present
Member, MD Anderson Cancer Center IRB Committee, 2023 - 2024
Patient Safety Officer, MD Anderson West Houston Quality and Safety Committee, 2023 - Present
Member, Internal Guideline Committee for Breast Lobular Carcinoma, Department of Breast Medical Oncology, 2022 - Present
Member, Multidisciplinary Breast Tumor Board planning committee -MD Anderson West Houston, 2022 - Present
Member, Wellness Working Group, Department of Breast Medical Oncology, 2021 - Present
Honors & Awards
2022 | Highest Award for Achievement, Dale Carnegie Effective Communications and Human Relations Program |
2018 | Outstanding Fellow Recognition Award, Texas Society of Clinical Oncology |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Chamani, IJ, Gannon, A, Connell, PT, Bisen, AK, Kovanci, E, Sangi-Haghpeykar, H, Woodard, TL, McKenzie, LJ. Dose-Dense Chemotherapy Regimen for Breast Cancer Associated with Significant Decline in Ovarian Reserve. Journal of adolescent and young adult oncology 13(3):465-468, 2024. PMID: 38112555.
- Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA. Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. Br J Cancer 119(8):928-936, 2018. e-Pub 2018. PMID: 30318513.
- Garcia S, Bisen A, Yan J, Xie XJ, Ramalingam S, Schiller JH, Johnson DH, Gerber DE. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. J Thorac Oncol 12(10):1489-1495, 2017. e-Pub 2017. PMID: 28802905.
Other Articles
- Bisen A, Claxton DF Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. Adv Exp Med Biol 779(None):179-96, 2013. PMID: 23288640.
Abstracts
- Bisen AK. Manuscript submission: Targeting the EGFR pathway in chemotherapy-resistant triple-negative breast cancer – a phase II study. Cancer Research Communications None(None):None, 2024. PMID: None.
- Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada B, Arun BK, Barcenas CH, Bisen A, Booser D, Tripathy D. Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancer. None None(None):None, 2022. PMID: None.
- Leitzel K, Ali S, Bisen A, Lomakin A, Simonyan V, Lipton A. Multiplex plasma biomarkers associated with bone metastasis from breast cancer. American Association for Cancer Research 71(24):None, 2011. PMID: None.
Patient Reviews
CV information above last modified October 28, 2024